HC Wainwright & Co. Maintains Buy on Kiora Pharmaceuticals, Lowers Price Target to $2
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Yi Chen maintains a 'Buy' rating on Kiora Pharmaceuticals (NASDAQ:KPRX), but has lowered the price target from $7 to $2.
August 14, 2023 | 10:38 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Despite the lowered price target from $7 to $2, HC Wainwright & Co. maintains a 'Buy' rating on Kiora Pharmaceuticals.
The news directly pertains to Kiora Pharmaceuticals and is important for investors as it provides an updated price target and reaffirms the 'Buy' rating. However, the significant reduction in price target may cause uncertainty among investors, potentially impacting the stock's short-term performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100